Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Revision as of 18:55, 18 May 2009 by Swilliams (talk | contribs)
Jump to navigation Jump to search

WikiDoc Resources for Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Articles

Most recent articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Most cited articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Review articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Articles on Unstable angina non ST elevation myocardial infarction anticoagulant therapy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Images of Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Photos of Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Podcasts & MP3s on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Videos on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Evidence Based Medicine

Cochrane Collaboration on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Bandolier on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

TRIP on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Clinical Trials

Ongoing Trials on Unstable angina non ST elevation myocardial infarction anticoagulant therapy at Clinical Trials.gov

Trial results on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Clinical Trials on Unstable angina non ST elevation myocardial infarction anticoagulant therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

NICE Guidance on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

NHS PRODIGY Guidance

FDA on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

CDC on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Books

Books on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

News

Unstable angina non ST elevation myocardial infarction anticoagulant therapy in the news

Be alerted to news on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

News trends on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Commentary

Blogs on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Definitions

Definitions of Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Patient Resources / Community

Patient resources on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Discussion groups on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Patient Handouts on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Directions to Hospitals Treating Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Risk calculators and risk factors for Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Healthcare Provider Resources

Symptoms of Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Causes & Risk Factors for Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Diagnostic studies for Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Treatment of Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Continuing Medical Education (CME)

CME Programs on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

International

Unstable angina non ST elevation myocardial infarction anticoagulant therapy en Espanol

Unstable angina non ST elevation myocardial infarction anticoagulant therapy en Francais

Business

Unstable angina non ST elevation myocardial infarction anticoagulant therapy in the Marketplace

Patents on Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Experimental / Informatics

List of terms related to Unstable angina non ST elevation myocardial infarction anticoagulant therapy

Cardiology Network

Discuss Unstable angina non ST elevation myocardial infarction anticoagulant therapy further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview of Anticoagulant Therapy in NSTEMI

ACC / AHA Guidelines (DO NOT EDIT) [1]

Class I

  1. Anticoagulant therapy should be added to antiplatelet therapy in UA / NSTEMI patients as soon as possible after presentation.
a. For patients in whom an invasive strategy is selected, regimens with established efficacy at a Level of Evidence: A include enoxaparin and UFH, and those with established efficacy at a Level of Evidence: B include bivalirudin and fondaparinux.
b. For patients in whom a conservative strategy is selected, regimens using either enoxaparin or UFH (Level of Evidence: A) or fondaparinux (Level of Evidence: B) have established efficacy.
c. In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, fondaparinux is preferable. (Level of Evidence: B)


Class IIa

  1. For UA / NSTEMI patients in whom an initial conservative strategy is selected, enoxaparin or fondaparinux is preferable to UFH as anticoagulant therapy, unless CABG is planned within 24 h. (Level of Evidence: B)

Sources

  • The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Eleveation Myocardial Infarction [1]

References

  1. 1.0 1.1 Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter |month= ignored (help)

Template:SIB

Template:WH Template:WS